News brief­ing: No­var­tis eyes ex­pan­sion for Eylea ri­val with PhI­II re­sults; Dupix­ent ob­tains BTD for EoE

No­var­tis re­port­ed pos­i­tive topline re­sults in a Phase III for its Eylea ri­val, a sign that the com­pa­ny is push­ing the brolu­cizum­ab com­pound, ap­proved last Oc­to­ber in the US, for a po­ten­tial la­bel ex­pan­sion.

Brolu­cizum­ab, sold as Beovu, is now be­ing stud­ied in di­a­bet­ic mac­u­lar ede­ma. No­var­tis said the 6 mg dose met its pri­ma­ry end­point of non-in­fe­ri­or­i­ty to 2 mg of Eylea in mean change in best-cor­rect­ed vi­su­al acu­ity (BC­VA) af­ter one year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER